| Followers | 25 |
| Posts | 2128 |
| Boards Moderated | 0 |
| Alias Born | 03/07/2014 |
Tuesday, January 16, 2024 5:05:05 PM
"Grifols SA has an analyst consensus of Moderate Buy, with a price target consensus of $16.26, representing an 89.5% upside. In a report issued on January 4, Barclays also upgraded the stock to Buy with a EUR18.00 price target."
Chart concurs with those price targets by the way.
https://markets.businessinsider.com/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-nyxoah-nyxh-grifols-sa-grfs-1032962325
Chart concurs with those price targets by the way.
https://markets.businessinsider.com/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-nyxoah-nyxh-grifols-sa-grfs-1032962325
Recent GRFS News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 06:35:37 PM
- Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease • GlobeNewswire Inc. • 03/17/2026 12:28:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/16/2025 02:26:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/30/2025 10:12:21 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2025 05:59:56 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2025 11:15:29 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2025 07:58:16 PM
